Physician profile
Sachin Kumar
NPI 1629483110
$620.59
in general payments reported to CMS, 2019-2025
10 companies · $23.71 in 2025
The $23.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $29.84 · 2023: $40.11 · 2024: $128 · 2025: $23.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $263.91 | 2019 | |
| Gilead Sciences, INC. | $88.76 | 2023-2024 | Veklury |
| Procyrion, INC. | $56.65 | 2024-2025 | Aortix System |
| Portola Pharmaceuticals, LLC | $45.17 | 2019 | |
| Vifor Pharma, INC. | $33.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.02 | 2019 | |
| Merck Sharp & Dohme LLC | $29.84 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.78 | 2019 | |
| Amgen INC. | $21.35 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachin Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.